Multiplexed POC Testing IVD Solution Performs Molecular and Immunoassays from Various Body Fluids on Single Platform

A hybrid in vitro diagnostics (IVD) solution for multiplexed point-of-care testing (xPOCT) can perform both molecular and immunoassays from several body fluids on a single platform. The hybrid and scalable technology aims to deliver lab-comparable test results in a single patient encounter, significantly reducing the diagnostic timeline.

Picodya’s B-Matrix diagnostic system is the world’s first POC hybrid solution that can run IVD tests, both immunoassays and molecular assays on the same device at lab-comparable quality, on multiple patient samples, simultaneously within minutes. The B-Matrix is designed to minimize turnaround time, and deliver better outcomes while lowering costs. The B-Matrix is powered by Picodya’s proprietary PicoFluidic technology which enables the system to operate at high capacity testing for a panel of markers simultaneously, using just pico volumes of reagents and controls. This allows for ultra-fast results within as quickly as 15 minutes and at a fraction of the cost for comparable tests. Additionally, the technology is scalable, making it suitable for all settings and throughputs.

Image: The hybrid and scalable B-Matrix system can perform both molecular and immunologic assays (Photo courtesy of Picodya)

The B-Matrix utilizes a unique Diagnostic Pack (DP) cartridge, the only PicoFluidic chip in the world that is capable of running hundreds of patient samples for a panel of syndromic tests using the same chip. The efficient use of minute reagent volumes by Picodya’s technology translates into substantial cost savings. Additionally, the system uses single-use Assay Packs (APs) pre-loaded with necessary reagents and a membrane slide for reactions to occur. Multiple APs, each containing a different patient sample, can be processed simultaneously for a chosen range of tests. The B-Matrix product suite is designed to meet the needs of healthcare providers in various environments, with platforms of varying sizes and throughputs. All B-Matrix platforms are built on the same core technology, ensuring compatibility with the same consumables and facilitating the introduction of new test assays.

Picodya’s B-Matrix has demonstrated its versatility through a feasibility study, confirming its ability to perform a wide array of immunoassays and molecular tests, including COVID-19, influenza, HBV, EBV, prostate cancer, and cardiologic markers. The system is being integrated into research facilities worldwide, to optimize diagnostic timelines and reduce costs. Picodya is advancing through its regulatory pathway, with post-approval plans to deploy the system across diverse healthcare settings and large-scale venues. The technology has already been implemented in NIH laboratories for global serologic surveillance, aiding in the real-time monitoring of human immune status and the detection of viral outbreaks.

"With our knowledge of the devastating impact of COVID-19 on global health and following years of research collaboration with the NIH for crisis preparedness, we are proud to proceed with the next phase of this important partnership," said Tzvika Barkai, Founder and Chief Executive Officer at Picodya. "We remain dedicated to enabling timely, precise, and comprehensive disease diagnosis capabilities to optimize potential outcomes. We plan to introduce the B-Matrix solution to additional research labs across the US, followed by the broader clinical market."

Related Links:
Picodya